What is the role of platelet inhibitors in acute coronary syndrome?

What is the role of platelet inhibitors in acute coronary syndrome?

• A. They are primarily vasodilators that improve coronary perfusion.
• B. They decrease platelet aggregation and inhibit thrombus formation by blocking certain platelet receptor sites.
• C. They directly increase heart rate to improve circulation.
• D. They enhance the coagulation cascade.

Answer: (B)

In acute coronary syndrome, a thrombus forms as platelets activate and accumulate at the, often ruptured, plaque, blocking blood flow to the heart muscle. Platelet inhibitors work by blocking receptors on the platelets that drive activation and aggregation, so far fewer platelets clump together to form a clot. This reduces thrombus growth and helps restore or preserve coronary perfusion. Aspirin lowers platelet activation by inhibiting thromboxane A2 production; P2Y12 inhibitors prevent ADP-mediated platelet activation; and glycoprotein IIb/IIIa inhibitors block the final step where platelets cross-link through fibrinogen. These actions directly target the clotting process on the platelet side, which is why they’re central to ACS management. They are not vasodilators, they don’t increase heart rate, and they don’t enhance the coagulation cascade; instead they counteract thrombosis to protect myocardial tissue.

In acute coronary syndrome, a thrombus forms as platelets activate and accumulate at the, often ruptured, plaque, blocking blood flow to the heart muscle. Platelet inhibitors work by blocking receptors on the platelets that drive activation and aggregation, so far fewer platelets clump together to form a clot. This reduces thrombus growth and helps restore or preserve coronary perfusion. Aspirin lowers platelet activation by inhibiting thromboxane A2 production; P2Y12 inhibitors prevent ADP-mediated platelet activation; and glycoprotein IIb/IIIa inhibitors block the final step where platelets cross-link through fibrinogen. These actions directly target the clotting process on the platelet side, which is why they’re central to ACS management. They are not vasodilators, they don’t increase heart rate, and they don’t enhance the coagulation cascade; instead they counteract thrombosis to protect myocardial tissue.